Evidence record · ER-GHRP-GH-009
Do GHRP-2, GHRP-6 and hexarelin release growth hormone?
GHRP-2, GHRP-6 and hexarelin acutely release growth hormone in people
GHRP-2, GHRP-6 and hexarelin can produce acute growth-hormone responses in small human studies. This supports a short-term pharmacodynamic effect, not muscle gain, fat loss, faster recovery or safe long-term use. The compounds have different response profiles and should not be treated as interchangeable.
Claim boundary
What this verdict covers
The verdict covers acute hormone concentrations after defined study compounds. It does not combine all secretagogues into one drug or extend the finding to clinical, physique or performance outcomes.
- Compound
- GHRP-2, GHRP-6 and hexarelin
- Population
- Adults in controlled pharmacology studies
- Outcome
- Acute circulating growth hormone
- Record ID
- ER-GHRP-GH-009
Evidence synthesis
What the research can support
Controlled human pharmacology studies reported growth-hormone responses to these secretagogues and interactions with endogenous pathways. The programmes were small and focused on endocrine response rather than long-term health or performance.
Why the confidence is moderate
Evidence is direct for the acute surrogate outcome but limited for duration, comparative effects, chronic safety and product equivalence.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-GHRP-GH-009 addresses one bounded question: Do GHRP-2, GHRP-6 and hexarelin release growth hormone?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 4 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Limited human, the verdict is Supported and confidence is Moderate. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Human GHRP-2 endocrine study | The study reported acute growth-hormone responses in people. | It did not test muscle gain or recovery. | 10 August 2026 |
| Human GHRP-6 response study | The study examined endocrine responses to GHRP-6. | Short-term hormone response is not a long-term benefit estimate. | 10 August 2026 |
| Human hexarelin study | The study measured hormone responses to hexarelin. | It does not establish broad clinical effectiveness or safety. | 10 August 2026 |
| WADA 2026 Prohibited List | Growth hormone-releasing peptides are prohibited at all times. | The list does not endorse a medical use. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on GHRP-2, GHRP-6 and hexarelin for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Controlled human pharmacology studies reported growth-hormone responses to these secretagogues and interactions with endogenous pathways. The programmes were small and focused on endocrine response rather than long-term health or performance. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is GHRP-2, GHRP-6 and hexarelin authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Growth hormone-releasing peptides and secretagogues are prohibited at all times under the WADA S2 category. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
Larger studies of individual, characterised compounds with prespecified clinical outcomes, adequate follow-up and transparent adverse-event reporting. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation